CoChat
Sign Up
Cited by 366Prostate Cancer Treatment and ResearchPI3K/AKT/mTOR signaling in cancerCancer, Lipids, and Metabolism

Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer

Open access
Sarker, Debashis, Reid, Alison H.M., Yap, Timothy A., de Bono, Johann S.·2009·Clinical Cancer Research
DOI 10.1158/1078-0432.ccr-08-0125
Open this paper in CoChat — free accountOpen PDF

Abstract

Despite recent advances in our understanding of the biological basis of prostate cancer, the management of the disease, especially in the castration-resistant phase, remains a significant challenge. Deregulation of the phosphatidylinositol 3-kinase pathway is increasingly implicated in prostate carcinogenesis. In this review, we detail the role of this pathway in the pathogenesis of prostate cancer and the rapidly evolving therapeutic implications of targeting it. In particular, we highlight the importance of the appropriate selection of agents and combinations, and the critical role of predictive and pharmocodynamic biomarkers.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-08-0125

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 70

  1. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
  2. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-19.
  3. Yap TA, Garrett MD, Walton MI, et al. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008;8: 393-412.
  4. Samuels Y, Wang Z, Bardelli A, et al. High fre- quency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
  5. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigene- sis. Nat Rev Cancer 2006;6:184-92.
  6. Suzuki H, Freije D, Nusskern DR, et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998;58:204-9.
  7. Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007;97:678-85.
  8. Bellacosa A, Kumar CC, Di CA, Testa JR. Activa- tion of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005;94: 29-86.
  9. Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008;321: 1499-502.
  10. Garcia-Echeverria C, Sellers WR. Drug discov- ery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008;27:5511-26.
  11. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27:5497-510.
  12. Zhao L, Vogt PK. Class I PI3K in oncogenic cel- lular transformation. Oncogene 2008;27:5486-96.
  13. Leslie NR, Batty IH, Maccario H, Davidson L, Downes CP. Understanding PTEN regulation: PIP2, polarity and protein stability. Onco- gene 2008;27:5464-76.
  14. Taplin ME. Androgen receptor: role and novel therapeutic prospects in prostate cancer. Expert Rev Anticancer Ther 2008;8:1495-508.
  15. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD. Collocation of an- drogen receptor gene mutations in prostate cancer. Clin Cancer Res 2001;7:1273-81.
  16. Kang Z, Janne OA, Palvimo JJ. Coregulator re- cruitment and histone modifications in transcrip- tional regulation by the androgen receptor. Mol Endocrinol 2004;18:2633-48.
  17. Shen MM, Abate-Shen C. Pten inactivation and the emergence of androgen-independent pros- tate cancer. Cancer Res 2007;67:6535-8.
  18. Majumder PK, Sellers WR. Akt-regulated path- ways in prostate cancer. Oncogene 2005;24: 7465-74.
  19. Cairns P, Okami K, Halachmi S, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997;57:4997-5000.
  20. Dong JT, Sipe TW, Hyytinen ER, et al. PTEN/ MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene 1998;17: 1979-82.
  21. Verhagen PC, van Duijn PW, Hermans KG, et al. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol 2006;208: 699-707.
  22. Yoshimoto M, Cutz JC, Nuin PA, et al. Inter- phase FISH analysis of PTEN in histologic sec- tions shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Gen- et Cytogenet 2006;169:128-37.
  23. Dong JT, Li CL, Sipe TW, Frierson HF, Jr. Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. Clin Cancer Res 2001;7:304-8.
  24. Feilotter HE, Nagai MA, Boag AH, Eng C, M ul ligan LM. An alysi s o f PT EN and the 10q23 region in primary prostate carcino- mas. Oncogene 1998;16:1743-8.
  25. Halvorsen OJ, Haukaas SA, Akslen LA. Com- bined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki- 67 and increased risk of recurrent disease in lo- calized prostate cancer. Clin Cancer Res 2003;9: 1474-9.
  26. Bertram J, Peacock JW, Fazli L, et al. Loss of PTEN is associated with progression to androgen independence. Prostate 2006;66: 895-902.
  27. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded prim ary pro state cancer correlates with high Gleason score and advanced stage. Cancer Res 1999;59:4291-6.
  28. Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer. Onco- gene 2006;25:329-37.
  29. Ayala G, Thompson T, Yang G, et al. High levels of phosphorylated form of Akt-1 in pros- tate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 2004;10:6572-8.
  30. Kreisberg JI, Malik SN, Prihoda TJ, et al. Phos- phorylation of Akt (Ser473) is an excellent pre- dictor of poor clinical outcome in prostate cancer. Cancer Res 2004;64:5232-6.
  31. Wang S, Gao J, Lei Q, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003;4:209-21.
  32. Di Cristofano A, De AM, Koff A, Cordon-Cardo C, Pandolfi PP. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 2001;27:222-4.
  33. Zhu Q, Youn H, Tang J, et al. Phosphoinositide 3-OH kinase p85α and p110β are essential for androgen receptor transactivation and tumor progression in prostate cancers. Oncogene 2008;27:4569-79.
  34. Jia S, Liu Z, Zhang S, et al. Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis. Nature 2008;454:776-9.
  35. Tomlins SA, Rhodes DR, Perner S, et al. Recur- rent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310:644-8.
  36. Han B, Mehra R, Dhanasekaran SM, et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identifi- cation of DDX5-4 fusion protein in prostate can- cer. Cancer Res 2008;68:7629-37.
  37. Attard G, Clark J, Ambroisine L, et al. Dupli- cation of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate can- cer. Oncogene 2008;27:253-63.
  38. King JC, Xu J, Wongvipat J, et al. Cooperativ- ity of TMPRSS2-ERG with P13-kinase pathway activation in prostate oncogenesis. Nat Genet 2009;41:524-6.
  39. Carver BS, Tran J, Gopalan A, et al. Aberrant ERG gene expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009;41:619-24.
  40. Richter R, Bistrian R, Escher S, et al. Quantum proteolytic activation of chemokine CCL15 by neutrophil granulocytes modulates mononucle- ar cell adhesiveness. J Immunol 2005;175: 1599-608.
  41. Roca H, Varsos Z, Pienta KJ. CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT- dependent survivin up-regulation. J Biol Chem 2008;283:25057-73.
  42. Lapointe J, Li C, Higgins JP, et al. Gene expres- sion profiling identifies clinically relevant sub- types of prostate cancer. Proc Natl Acad Sci U S A 2004;101:811-6.
  43. Jendrossek V, Henkel M, Hennenlotter J, et al. Analysis of complex protein kinase B signalling pathways in human prostate cancer samples. BJU Int 2008;102:371-82.
  44. De Bono JS, Attard G, Adjei A, et al. Potential applications for circulating tumor cells expres- sing the insulin-like growth factor-I receptor. Clin Cancer Res 2007;13:3611-6.
  45. Bedolla R, Prihoda TJ, Kreisberg JI, et al. De- termining risk of biochemical recurrence in pros- tate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Can- cer Res 2007;13:3860-7.
  46. Hattori S, Iida N, Kosako H. Identification of protein kinase substrates by proteomic approaches. Expert Rev Proteomics 2008;5: 497-505.
  47. Grubb RL, Calvert VS, Wulkuhle JD, et al. Sig- nal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 2003; 3:2142-6.
  48. Raynaud FI, Eccles S, Clarke PA, et al. Pharma- cologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007;67:5840-50.
  49. Guillard S, Clarke PA, Te Poele R, et al. Molec- ular pharmacology of phosphatidylinositol 3-ki- nase inhibition in human glioma. Cell Cycle 2009;8:443-53.
  50. Folkes AJ, Ahmadi K, Alderton WK, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methane- sulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl- thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I P13 kinase for the treatment of cancer. J Med Chem 2008;51:5522-32.
  51. Raynaud F, Eccles SA, Patel S, et al. Biological properties of potent inhibitors of class I phospha- tidylinositide 3-kinases: from P1-103 through PI- 540, PI-620 to the oral agent GDC-0941. Mol Can- cer Ther 2009;8 (in press).
  52. Sarker D, Kristeleit R, Mazina K, et al. A Phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic activity (PD) of the oral pan-phosphoinositide-3 kinase (P13K) inhibitor GDC-0941. J Clin Oncol 2009;27:15s(suppl; abstr 3538).
  53. Lee JY, Engelman JA, Cantley LC. Biochemis- try. P13K charges ahead. Science 2009;317:206-7.
  54. Amzel Lm, Huang CH, Mandelker D, Lengauer C, Gabelli SB, Vogelstein B. Structural compari- sons of class I phosphoinositide 3-kinases. Nat Rev Cancer 2008;8:665-9.
  55. Le Page C, Koumakpayi IH, Alam-Fahmy M, et al. Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of pros- tate cancer patients. Br J Cancer 2006;94:1906-12.
  56. Rhodes N, Heerding DA, Duckett DR, et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activi- ty. Cancer Res 2008;68:2366-74.
  57. Tolcher AW, Yap TA, Fearen I, et al. A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (AKti), in patients (pts) with advanced solid tumor (ST). J Clin Oncol 2009;27:15s, (suppl; abstr 3503)
  58. O'Reilly KE, Rojo F, She QB, et al. mTOR inhi- bition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66: 1500-8.
  59. LoRusso P, Markman B, Tabernero J, et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a P13K/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors. J Clin Oncol 2009;27:15s(suppl; abstr 3502).
  60. Yu K, Toral-Barza L, Shi C, Zhang WG, Zask A. Response and determinants of cancer cell sus- ceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strat- egy. Cancer Biol Ther 2008;7:307-15.
  61. Gao H, Ouyang X, Banach-Petrosky WA, et al. Combinatorial activities of Akt and B-Raf/Erk sig- naling in a mouse model of androgen-indepen- dent prostate cancer. Proc Natl Acad Sci U S A 2006;103:14477-82.
  62. Schayowitz A, Sabnis G, Njar VC, Brodie AM. Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone inde- pendence in vitro. Mol Cancer Ther 2008;7: 121-32.
  63. Sarker D, Workman P. Pharmacodynamic bio- markers for molecular cancer therapeutics. Adv Cancer Res 2007;96:213-68.
  64. Hidalgo M. New target, new drug, old para- digm. J Clin Oncol 2004;22:2270-2.
  65. Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol 2004;22:4217-26.
  66. Mellinghoff IK, Sawyers CL. TORward AK- Tually useful mouse models. Nat Med 2004;10: 579-80.
  67. Oyama N, Ponde DE, Dence C, Kim J, Tai YC, Welch MJ. Monitoring of therapy in androgen- dependent prostate tumor model by measuring tumor proliferation. J Nucl Med 2004;45:519-25.
  68. Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymi- dine ([()F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002;8:3315-23.
  69. Beloueche-Babari M, Jackson LE, Al-Saffar NM, et al. Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase sig- naling in human breast cancer cells. Mol Cancer Ther 2006;5:187-96.
  70. Graupera M, Guillermet-Guibert J, Foukas LC, et al. Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration. Nature 2008;453:662-6.

Cited by

Sorted by citations

Authors
Sarker, D., Reid, A. H. M., Yap, T. A., & de Bono, J. S.
Affiliations
  • Royal Marsden NHS Foundation Trust (GB)
  • Authors' Affiliation: Section of Medicine and Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, United Kingdom
ORCID
Venue
Clinical Cancer Research
Publisher
American Association for Cancer Research (AACR)
Published
2009-07-29
Volume
15
Issue
15
Pages
4799-4805
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
DOI
10.1158/1078-0432.ccr-08-0125
OpenAlex
W2100237319
Cited by
366
References
7
Citations by year
2026: 3 · 2025: 11 · 2024: 11 · 2023: 14 · 2022: 16 · 2021: 26 · 2020: 19 · 2019: 16 · 2018: 24 · 2017: 26 · 2016: 14 · 2015: 27 · 2014: 26 · 2013: 36 · 2012: 30
FWCI
4.89
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion)
Funders
  • NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
  • Cancer Research UK
  • National Institute for Health and Care Research
  • Imperial Experimental Cancer Medicine Centre
  • Medical Research Council
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
PI3K/Akt signaling, prostate cancer, castration-resistant prostate cancer, phosphatidylinositol 3-kinase, targeted therapy, combination therapy, predictive biomarkers, pharmacodynamic biomarkers, prostate carcinogenesis
MeSH terms
Transcriptional Regulator ERG, Phosphoinositide-3 Kinase Inhibitors, Humans, Male, Prostatic Neoplasms, Receptors, Androgen, Serine Endopeptidases, Signal Transduction, Oncogene Proteins, Fusion, Trans-Activators, Chemokines, Phosphatidylinositol 3-Kinases, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, Androgen Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review